DNLI Denali Therapeutics Inc.: institutional ownership and insider trading
318 funds reported holding $4.73B of Denali Therapeutics Inc. in their latest 13F filings; in Q2 2026 funds net bought $236M, with 52 new positions and 28 funds selling out; over the last 12 months insiders bought $0 and sold $1.30M on the open market.
Famous investors holding DNLI
- Izzy Englander (Millennium Management): $29.0M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $15.4M, 0.0% of the portfolio
Largest institutional holders of DNLI
- Banque Cantonale Vaudoise — $461M
- T. Rowe Price Investment Management, Inc. — $416M
- BlackRock, Inc. (BLK) — $361M
- BAILLIE GIFFORD & CO — $308M
- VANGUARD GROUP INC — $216M
- STATE STREET CORP (STT, STT-PG) — $181M
- Temasek Holdings (Private) Ltd — $180M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $167M
- VANGUARD CAPITAL MANAGEMENT LLC — $161M
- FMR LLC — $117M
Recent DNLI insider trades
- Sep 4, 2026: Chin Peter Scott sold 1,654 shares ($36.9K)
- Sep 2, 2026: Thornberry Nancy sold 11,439 shares ($262K)
- Sep 1, 2026: Schuth Alexander O. sold 2,768 shares ($64.9K)
- Aug 11, 2026: Schuth Alexander O. sold 2,857 shares ($71.6K)
5%+ owners
- T. Rowe Price Investment Management, Inc.: 10.2% (Schedule 13G/A, filed Jul 8, 2026)
- BAILLIE GIFFORD & CO: 7.5% (Schedule 13G/A, filed Aug 4, 2026)